Cargando…

Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease

BACKGROUND: Matching-adjusted indirect comparison (MAIC) is a methodology for cross-study comparisons after adjusting for baseline characteristic imbalances. It is a comparative analytical approach used across therapeutic areas absent head-to-head trial outcomes. OBJECTIVES: To compare the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	White, Darrell E, Hendrix, Laura H, Sun, Lucille, Tam, Iris, Macsai, Marian, Gibson, Andrea A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394217/ https://www.ncbi.nlm.nih.gov/pubmed/36030415 http://dx.doi.org/10.18553/jmcp.2022.22208

Ejemplares similares

OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use
por: Epitropoulos, Alice T, et al.
Publicado: (2022)

OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2
por: Schallhorn, Julie M, et al.
Publicado: (2023)

Semi-PBPK Modeling and Simulation to Evaluate the Local and Systemic Pharmacokinetics of OC-01(Varenicline) Nasal Spray
por: Wu, Xiaofei, et al.
Publicado: (2022)

Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
por: Sheppard, John D., et al.
Publicado: (2023)

A Single Administration of OC-01 (Varenicline Solution) Nasal Spray Induces Short-Term Alterations in Conjunctival Goblet Cells in Patients with Dry Eye Disease
por: Dieckmann, Gabriela M., et al.
Publicado: (2022)

Does Menopausal Status Affect Dry Eye Disease Treatment Outcomes with OC-01 (Varenicline Solution) Nasal Spray? A Post Hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials
por: Nijm, Lisa M., et al.
Publicado: (2022)

ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
por: Wirta, David, et al.
Publicado: (2022)

Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease
por: Hauswirth, Scott G, et al.
Publicado: (2023)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Varenicline Solution Nasal Spray: A Review in Dry Eye Disease
por: Frampton, James E.
Publicado: (2022)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols, Kelly K, et al.
Publicado: (2018)

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis
por: Li, Jing-Xing, et al.
Publicado: (2022)

Could APO-varenicline and cytisine be solutions for the shortage of varenicline in Brazil?
por: Corrêa, Paulo César Rodrigues Pinto, et al.
Publicado: (2023)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Publicado: (2018)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials
por: Holland, Edward J., et al.
Publicado: (2021)

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra(®)) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
por: Hovanesian, John A, et al.
Publicado: (2021)

To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital
por: Sruthi, Vadlakonda, et al.
Publicado: (2020)

The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis
por: Bashrahil, Bader, et al.
Publicado: (2023)

Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex
por: Kato, C. O. Sayaka, et al.
Publicado: (2018)

Allergy to ophthalmic solutions
por: Lapeere, Hilde, et al.
Publicado: (2014)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett, Ivonne V, et al.
Publicado: (2018)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Oxymetazoline hydrochloride ophthalmic solution, 0.1%, boosts the effects of botulinum toxin on blepharospasm: a case series
por: Sung, Jonathan, et al.
Publicado: (2022)

Influence of container structures and content solutions on dispensing time of ophthalmic solutions
por: Yoshikawa, Keiji, et al.
Publicado: (2010)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline
por: Carlson, Eric C., et al.
Publicado: (2023)

Ophthalmic regional blocks: management, challenges, and solutions
por: Palte, Howard D
Publicado: (2015)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Lifitegrast: a novel drug for patients with dry eye disease
por: Haber, Stacy L., et al.
Publicado: (2019)

Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series
por: Go, Camille Celeste, et al.
Publicado: (2020)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

Development and Evaluation of a Chloramphenicol Hypertonic Ophthalmic Solution
por: Jithan, A. V., et al.
Publicado: (2008)

Stability of Ophthalmic Atropine Solutions for Child Myopia Control
por: Berton, Baptiste, et al.
Publicado: (2020)

In vitro amoebicidal effects of arabinogalactan-based ophthalmic solution
por: Reyes-Batlle, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_crbiovohsih97ugopj4g2rkhcb